3933 — United Laboratories International Holdings Share News
0.000.00%
Last trade - 00:00- HK$14.32bn
- HK$8.41bn
- CNY13.21bn
Brief: United Laboratories International Says Roxithromycin Capsules Passed Consistency Evaluation Conducted By China's NMPA
Brief: United Laboratories International Gets Approval For Clinical Trial Of UBT251 Injection
Brief: United Laboratories International Says FDA Approves IND For Tul108 Injection
Brief: United Laboratories International Says Moxifloxacin Hydrochloride Eye Drops Submitted By Unit Approved By China's NMPA
Brief: United Laboratories International Says Unit's Levofloxacin Eye Drops Approved By NMPA
Brief: United Laboratories International Says Cefoperazone Sodium And Sulbactam Sodium For Injection Passed Consistency Evaluation By NMPA
Brief: United Laboratories International Gets China Approval For UBT37034 Clinical Trial
Brief: United Laboratories International Posts H1 Net Income Of RMB1,894.3 MLN
Brief: United Laboratories International Expects Net Profit Of RMB1.85 Bln For H1
HK-listed United Laboratories falls on discounted share sale
Brief: United Laboratories International Announces Placing 156 Million Shares At HK$14.16 Per Share
Brief: United Laboratories International Updates On Amoxicillin Sodium And Clavulanate Potassium
Brief: United Laboratories International Flaunts U.S. FDA Approval Of IND For UBT37034 Injection
Brief: United Laboratories International Says United Biotechnology Got Upfront Payment From Novo Nordisk
Brief: United Laboratories International Says Group's Product Cefotaxime Sodium For Injection Passed Consistency Evaluation
Brief: United Laboratories International Says Final Dividend Of RMB28 Cents Per Share
Brief: United Laboratories International Declares Special Dividend
Brief: United Laboratories International Announces Exclusive License Agreement With Novo Nordisk
Brief: United Laboratories and Novo Nordisk announce exclusive license agreement for UBT251, a GLP-1/GIP/glucagon triple receptor agonist